HER2-Negative Breast Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
DelveInsight’s, “HER2-Negative Breast Cancer Pipeline Insight 2023” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in the HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Negative Breast Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the HER2-Negative Breast Cancer Pipeline Report
- DelveInsight’s HER2-Negative Breast Cancer pipeline report depicts a robust space with 85+ active players working to develop 85+ pipeline therapies for HER2-Negative Breast Cancer treatment.
- The leading companies working in the HER2-Negative Breast Cancer Market include AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others.
- Promising HER2-Negative Breast Cancer Pipeline Therapies in the various stages of development include MM-121, Paclitaxel, BGB-290, AZD9833, Fulvestrant, Anastrozole, OP-1250, and others.
- November 2023: Oana Danciu announced a study of Phase 2 clinical trials for Ribociclib, Fulvestrant, Anastrozole, Letrozole, and Exemestane. This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer. A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer.
- October 2023: AstraZeneca announced a study of Phase 3 clinical trials for AZD9833 and Anastrozole. The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone receptor-positive (ER-positive), human epidermal growth factor 2-negative (HER2-negative) advanced/metastatic breast cancer.
- October 2023: SynDevRx Inc. announced a study of Phase 1 & 2 clinical trials for Evexomostat. The purpose of this study is to characterize the safety of the triplet drug combination (alpelisib, fulvestrant plus evexomostat), to test whether evexomostat, when given in combination with alpelisib and fulvestrant will reduce the number and severity of hyperglycemic events and/or reduce the number of anti-diabetic medications needed to control the hyperglycemia for patients deemed at risk for alpelisib-induced hyperglycemia (baseline elevated HbA1c or well-controlled type 2 diabetes), and to assess preliminary anti-tumor efficacy and changes in key biomarkers and quality of life in this patient population.
Request a sample and discover the recent advances in HER2-Negative Breast Cancer Treatment Drugs @ HER2-Negative Breast Cancer Pipeline Report
In the HER2-Negative Breast Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-Negative Breast Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
HER2-Negative Breast Cancer Overview
HER2-Negative Breast Cancer is classified as HR-positive if its cells have receptors for the hormones estrogen and/or progesterone along with no expression of the human epidermal growth factor receptor 2 (HER2). Immunohistochemistry (IHC) test and/or Fluorescent in situ hybridization (FISH) is done to find out if cancer cells have estrogen and progesterone receptors.
Find out more about HER2-Negative Breast Cancer Therapeutics Assessment @ HER2-Negative Breast Cancer Preclinical and Discovery Stage Products
HER2-Negative Breast Cancer Emerging Drugs Profile
- Capivasertib + Fulvestrant: AstraZeneca
- Dalpiciclib: Jiangsu HengRui Medicine
HER2-Negative Breast Cancer Pipeline Therapeutics Assessment
There are approx. 85+ key companies which are developing the HER2-Negative Breast Cancer therapies. The HER2-Negative Breast Cancer companies which have their HER2-Negative Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Jiangsu HengRui Medicine.
DelveInsight’s HER2-Negative Breast Cancer pipeline report covers around 85+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
HER2-Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
HER2-Negative Breast Cancer Pipeline Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Learn more about the emerging HER2-Negative Breast Cancer Pipeline Therapies @ HER2-Negative Breast Cancer Clinical Trials Assessment
Scope of the HER2-Negative Breast Cancer Pipeline Report
- Coverage- Global
- HER2-Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- HER2-Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- HER2-Negative Breast Cancer Companies- AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, Chia Tai Tianqing Pharmaceutical, Tyme, Radius Pharmaceuticals, H3 Biomedicine, Eli Lilly and Company, Eagle Pharmaceuticals, and others.
- HER2-Negative Breast Cancer Pipeline Therapies- MM-121, Paclitaxel, BGB-290, AZD9833, Fulvestrant, Anastrozole, OP-1250, and others.
Dive deep into rich insights for new drugs for HER2-Negative Breast Cancer Treatment, Visit @ HER2-Negative Breast Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- HER2-Negative Breast Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- HER2-Negative Breast Cancer – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- HER2-Negative Breast Cancer Collaboration Deals
- Late Stage Products (Phase III)
- Capivasertib + Fulvestrant: AstraZeneca
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- Inavolisib: Roche
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Afuresertib + Fulvestrant: Laekna
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- HER2-Negative Breast Cancer Key Companies
- HER2-Negative Breast Cancer Key Products
- HER2-Negative Breast Cancer- Unmet Needs
- HER2-Negative Breast Cancer- Market Drivers and Barriers
- HER2-Negative Breast Cancer- Future Perspectives and Conclusion
- HER2-Negative Breast Cancer Analyst Views
- HER2-Negative Breast Cancer Key Companies
- Appendix
For further information on the HER2-Negative Breast Cancer Pipeline therapeutics, reach out to HER2-Negative Breast Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/her2-negative-breast-cancer-market
){kind=link}